menu
    • menu

    Company profile for DiaMedica Therapeutics

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    DiaMedica Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with a focus on neurological and kidney diseases. The Company is developing DM199, a recombinant (synthetic) human protein, for patients suffering from neurological and kidney diseases. DM199 has undergone clinical testing that d...
    DiaMedica Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with a focus on neurological and kidney diseases. The Company is developing DM199, a recombinant (synthetic) human protein, for patients suffering from neurological and kidney diseases. DM199 has undergone clinical testing that demonstrates its exceptional safety as a potential treatment for a variety of disorders. The Company is positing DM199 for the treatment of diabetic nephropathy and post-insult treatment from acute ischemic stroke (AIS).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    DiaMedica TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Carlson Parkway, Suite 260 Minneapolis, MN 55447
    Telephone
    Telephone
    763-496-5454
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.diamedica.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Diamedica Therapeutics Joins March Investor Conferences
    Diamedica Therapeutics Joins March Investor Conferences

    24 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260224688070/en/DiaMedica-Therapeutics-to-Participate-in-Upcoming-March-Investor-Conferences

    BUSINESSWIRE
    24 Feb 2026
    Share Share
    DiaMedica Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)
    DiaMedica Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)

    16 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260116177783/en/DiaMedica-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    16 Jan 2026
    Share Share
    DiaMedica Updates DM199 Preeclampsia Program After FDA Meeting
    DiaMedica Updates DM199 Preeclampsia Program After FDA Meeting

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251218113728/en/DiaMedica-Therapeutics-Provides-DM199-Preeclampsia-Program-Update-Following-Pre-IND-Meeting-with-FDA

    BUSINESSWIRE
    18 Dec 2025
    Share Share
    Diamedica Therapeutics Reveals Q3 2025 Financials & Business
    Diamedica Therapeutics Reveals Q3 2025 Financials & Business

    12 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112164599/en/DiaMedica-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Highlights

    BUSINESSWIRE
    12 Nov 2025
    Share Share
    Diamedica Therapeutics To Join Jefferies Global Healthcare Conf
    Diamedica Therapeutics To Join Jefferies Global Healthcare Conf

    10 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251110063933/en/DiaMedica-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference-in-London

    BUSINESS WIRE
    10 Nov 2025
    Share Share
    Diamedica Therapeutics To Release Q3 2025 Financial Update
    Diamedica Therapeutics To Release Q3 2025 Financial Update

    06 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251106639614/en/DiaMedica-Therapeutics-to-Report-Third-Quarter-2025-Financial-Results-and-Provide-a-Business-Update-November-13-2025

    BUSINESSWIRE
    06 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search